Ruggero Ridolfi Selected Research

Ruggero Ridolfi Research Topics

Disease

28	Melanoma (Melanoma, Malignant) 01/2017 - 03/2002
21	Neoplasms (Cancer) 09/2014 - 03/2003
3	Renal Cell Carcinoma (Grawitz Tumor) 09/2014 - 01/2004
3	Neoplasm Metastasis (Metastasis) 05/2012 - 03/2003
3	Diarrhea 01/2012 - 09/2009
2	Disease Progression 05/2014 - 08/2006
2	Colorectal Neoplasms (Colorectal Cancer) 01/2014 - 07/2004
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2011 - 02/2006
1	Spontaneous Abortion (Miscarriage) 03/2015
1	Metabolic Diseases (Metabolic Disease) 03/2015
1	Autistic Disorder (Autism) 03/2015
1	Brain Neoplasms (Brain Tumor) 09/2012
1	Kidney Neoplasms (Kidney Cancer) 05/2012
1	Thrombocytopenia 1 01/2012
1	Uveal melanoma 01/2012
1	Cardiotoxicity 04/2010
1	Cardiovascular Diseases (Cardiovascular Disease) 04/2010
1	Breast Neoplasms (Breast Cancer) 04/2010
1	Hypersensitivity (Allergy) 01/2010
1	Colitis 09/2009
1	Splenomegaly 09/2008
1	Lymphadenopathy 09/2008
1	Thrombocytopenia (Thrombopenia) 02/2006
1	Anemia 02/2006
1	Neutropenia 02/2006
1	Liver Diseases (Liver Disease) 12/2003
1	Fever (Fevers) 03/2002
1	Hyperthermia 03/2002
1	Arthralgia (Joint Pain) 03/2002
1	Myalgia 03/2002

Drug/Important Bio-Agent (IBA)

11	Interleukin-2 (IL2)IBA 09/2014 - 03/2002
8	IpilimumabIBA 05/2014 - 09/2009
4	VaccinesIBA 01/2017 - 01/2010
4	CytokinesIBA 09/2014 - 08/2006
4	Neoplasm Antigens (Tumor Antigens)IBA 09/2014 - 12/2003
4	keyhole-limpet hemocyanin (keyhole limpet hemocyanin)IBA 05/2013 - 08/2006
3	AntigensIBA 09/2014 - 06/2010
2	AntibodiesIBA 01/2017 - 02/2008
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2014 - 03/2002
2	Gemcitabine FDA Link 01/2014 - 02/2006
2	Temozolomide (Temodar)FDA LinkGeneric 05/2013 - 08/2004
2	fotemustine (Muphoran)IBA 09/2012 - 04/2009
2	SteroidsIBA 01/2012 - 09/2009
2	Budesonide (Pulmicort)FDA LinkGeneric 01/2012 - 09/2009
2	Cisplatin (Platino)FDA LinkGeneric 04/2009 - 03/2002
2	Interferon-alpha (Interferon Alfa)IBA 04/2009 - 08/2004
2	InterferonsIBA 02/2006 - 03/2002
2	Dacarbazine (DIC)FDA LinkGeneric 08/2004 - 03/2002
1	Environmental Pollutants (Pollutants, Environmental)IBA 03/2015
1	Biomarkers (Surrogate Marker)IBA 09/2014
1	MicroRNAs (MicroRNA)IBA 06/2014
1	dabrafenibIBA 05/2014
1	VemurafenibIBA 05/2014
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2014
1	Fluorouracil (Carac)FDA LinkGeneric 01/2014
1	Alanine (L-Alanine)FDA Link 01/2012
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2012
1	Dihydrotachysterol (AT 10)IBA 01/2012
1	Monoclonal AntibodiesIBA 01/2012
1	Histocompatibility Antigens Class IIIBA 06/2010
1	Peptides (Polypeptides)IBA 06/2010
1	HLA-DR Antigens (HLA-DR)IBA 06/2010
1	Immunoglobulin G (IgG)IBA 06/2010
1	Epirubicin (Ellence)FDA LinkGeneric 04/2010
1	liposomal doxorubicin (Doxil)FDA Link 04/2010
1	AnthracyclinesIBA 04/2010
1	Capecitabine (Xeloda)FDA Link 04/2010
1	Messenger RNA (mRNA)IBA 01/2010
1	Cancer VaccinesIBA 01/2010
1	Proteins (Proteins, Gene)FDA Link 01/2010
1	Interleukin-8 (Interleukin 8)IBA 08/2006
1	Interleukin-12 (IL 12)IBA 08/2006
1	Interleukin-10 (Interleukin 10)IBA 08/2006
1	Interleukin-6 (Interleukin 6)IBA 08/2006
1	Interferon alpha-2 (Roferon-A)FDA Link 02/2006
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 02/2006
1	Carboplatin (JM8)FDA LinkGeneric 02/2006
1	Paclitaxel (Taxol)FDA LinkGeneric 02/2006
1	Alkylating AgentsIBA 08/2004
1	Environmental BiomarkersIBA 07/2004
1	Fibrinogen (Factor I)FDA Link 12/2003
1	InterleukinsIBA 03/2003
1	Fas Ligand Protein (Fas Ligand)IBA 03/2003
1	Carmustine (FIVB)FDA Link 03/2002

Therapy/Procedure

10	Immunotherapy 06/2014 - 03/2002
9	Therapeutics 01/2013 - 03/2002
8	Drug Therapy (Chemotherapy) 01/2014 - 03/2002
6	Biological Therapy 12/2013 - 02/2008
2	Radiotherapy 09/2014 - 07/2014
1	Retreatment 05/2014
1	EAP protocol 10/2013
1	Withholding Treatment 06/2012
1	Erythrocyte Transfusion 02/2006
1	Nephrectomy 01/2004
1	Metastasectomy 03/2003
1	Intralesional Injections 03/2002